LINCS Pilot Phase Joint Project: Sensitivity measures of six breast cancer cell lines to a library of small molecule kinase inhibitors (single drug treatments). Dataset 13 of 15: Mean cell count and mean normalized growth rate inhibition values across biological replicate 3. - Dataset (ID:20250)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Small Molecule | Small Mol Concentration | Small Mol Conc Unit | LJP Library Plate | Timepoint | Timepoint Unit | Mean Total Cell Count Before Treatment | Mean Total Cell Count After Treatment | Mean Total Control Cell Count | Mean Relative Cell Count | Mean Normalized Growth Rate Inhibition Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| SK-BR-3 | CP724714 | 1.11 | uM | LJP5 | 72 | hr | 1401 | 2141 | 4245 | 0.5061 | 0.3052 |
| SK-BR-3 | CP724714 | 10 | uM | LJP5 | 72 | hr | 1401 | 1398 | 4245 | 0.3282 | -0.0075 |
| SK-BR-3 | Alvocidib | 0.04 | uM | LJP6 | 72 | hr | 1401 | 1580 | 4168 | 0.3793 | 0.0795 |
| SK-BR-3 | Alvocidib | 3.33 | uM | LJP6 | 72 | hr | 1401 | 903 | 4168 | 0.2170 | -0.2442 |
| SK-BR-3 | Alvocidib | 10 | uM | LJP6 | 72 | hr | 1401 | 970 | 4168 | 0.2330 | -0.2090 |
| SK-BR-3 | GW843682X | 0.12 | uM | LJP6 | 72 | hr | 1401 | 2267 | 4168 | 0.5435 | 0.3565 |
| SK-BR-3 | GW843682X | 0.37 | uM | LJP6 | 72 | hr | 1401 | 1457 | 4168 | 0.3490 | 0.0225 |
| SK-BR-3 | GW843682X | 10 | uM | LJP6 | 72 | hr | 1401 | 1734 | 4168 | 0.4157 | 0.1431 |
| SK-BR-3 | HG-5-113-01 | 0.04 | uM | LJP5 | 72 | hr | 1401 | 3952 | 4245 | 0.9310 | 0.9123 |
| SK-BR-3 | HG-5-113-01 | 0.37 | uM | LJP5 | 72 | hr | 1401 | 3418 | 4245 | 0.8048 | 0.7437 |
| SK-BR-3 | HG-5-113-01 | 1.11 | uM | LJP5 | 72 | hr | 1401 | 1494 | 4245 | 0.3516 | 0.0379 |
| SK-BR-3 | HG-5-88-01 | 1.11 | uM | LJP6 | 72 | hr | 1401 | 3503 | 4168 | 0.8403 | 0.7903 |
| SK-BR-3 | HG-5-88-01 | 3.33 | uM | LJP6 | 72 | hr | 1401 | 3630 | 4168 | 0.8713 | 0.8325 |
| SK-BR-3 | HG-6-64-01 | 0.04 | uM | LJP6 | 72 | hr | 1401 | 4507 | 4168 | 1.0819 | 1.1028 |
| SK-BR-3 | HG-6-64-01 | 0.12 | uM | LJP6 | 72 | hr | 1401 | 3544 | 4168 | 0.8505 | 0.8041 |
| SK-BR-3 | HG-6-64-01 | 3.33 | uM | LJP6 | 72 | hr | 1401 | 2258 | 4168 | 0.5420 | 0.3530 |
| SK-BR-3 | HG-6-64-01 | 10 | uM | LJP6 | 72 | hr | 1401 | 516 | 4168 | 0.1238 | -0.4732 |
| SK-BR-3 | Neratinib | 0.12 | uM | LJP5 | 72 | hr | 1401 | 1511 | 4245 | 0.3564 | 0.0471 |
| SK-BR-3 | Neratinib | 0.37 | uM | LJP5 | 72 | hr | 1401 | 1408 | 4245 | 0.3327 | 0.0029 |
| SK-BR-3 | JW-7-24-1 | 0.04 | uM | LJP6 | 72 | hr | 1401 | 3052 | 4168 | 0.7319 | 0.6391 |
| SK-BR-3 | JW-7-24-1 | 0.12 | uM | LJP6 | 72 | hr | 1401 | 3356 | 4168 | 0.8056 | 0.7434 |
| SK-BR-3 | JW-7-24-1 | 1.11 | uM | LJP6 | 72 | hr | 1401 | 2594 | 4168 | 0.6217 | 0.4773 |
| SK-BR-3 | JW-7-24-1 | 3.33 | uM | LJP6 | 72 | hr | 1401 | 2131 | 4168 | 0.5111 | 0.3046 |
| SK-BR-3 | PF562271 | 10 | uM | LJP6 | 72 | hr | 1401 | 1199 | 4168 | 0.2874 | -0.0955 |
| SK-BR-3 | PF562271 | 3.33 | uM | LJP6 | 72 | hr | 1401 | 1444 | 4168 | 0.3466 | 0.0194 |